Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study.

• The long-term mortality in adults treated with recombinant GH during childhood has been poorly investigated. Recently released data from the French part of the European Union Safety and Appropriateness of GH treatments in Europe (EU SAGhE) study have raised concerns on the long-term safety of GH treatment.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Pediatrik (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Pediatrics (hsv//eng)

Nyckelord

Adolescent

Adult

Adverse Drug Reaction Reporting Systems

statistics & numerical data

Belgium

epidemiology

Cause of Death

trends

Child

Cohort Studies

Dwarfism

Pituitary

drug therapy

epidemiology

mortality

Europe

epidemiology

Female

Growth Disorders

drug therapy

epidemiology

mortality

Human Growth Hormone

adverse effects

deficiency

therapeutic use

Humans

Infant

Newborn

Infant

Small for Gestational Age

growth & development

Male

Netherlands

epidemiology

Pilot Projects

Recombinant Proteins

adverse effects

therapeutic use

Survival Rate

trends

Sweden

epidemiology

Time Factors

Young Adult

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)